"10.1371_journal.pone.0037916","plos one","2012-05-29T00:00:00Z","Francesca Calabrese; Gianluigi Guidotti; Raffaella Molteni; Giorgio Racagni; Michele Mancini; Marco Andrea Riva","Center of Neuropharmacology, Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy; Medical Department, Eli Lilly Italia S.p.A., Sesto Fiorentino, Italy; Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milan, Italy","Conceived and designed the experiments: FC RM GR MM MAR. Performed the experiments: FC GG RM. Analyzed the data: FC RM MAR. Contributed reagents/materials/analysis tools: FC GG. Wrote the paper: FC MAR.","The authors have read the journal’s policy and have the following conflicts: Dr. Michele Mancini is an employee of Eli Lilly Italia holding Eli Lilly nonqualified stock option shares. Eli Lilly markets duloxetine as Cymbalta. There are no patents, products in development or other marketed products to declare. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","05","Francesca Calabrese","FC",6,TRUE,5,3,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
